A 10-year survey on lichen planus pemphigoides in Iran: A therapeutic conundrum

Kamran Balighi^{1

2}, Ali Mousavi¹, Parvaneh Hatami¹, Maryam Daneshpazhooh^{1

2}, Maryam Ghiasi^{1

2}, Kambiz Kamyab Hesari^{1

3}, Zeinab Aryanian^{1

4}, Mohammadreza Kavyani¹

Affiliations

¹ Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
² Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
³ Department of Dermatopathology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.

Kamran Balighi et al. Dermatol Ther. 2022 Jul.

. 2022 Jul;35(7):e15387.

doi: 10.1111/dth.15387. Epub 2022 May 18.

Kamran Balighi^{1

2}, Ali Mousavi¹, Parvaneh Hatami¹, Maryam Daneshpazhooh^{1

2}, Maryam Ghiasi^{1

2}, Kambiz Kamyab Hesari^{1

3}, Zeinab Aryanian^{1

4}, Mohammadreza Kavyani¹

¹ Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
² Department of Dermatology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
³ Department of Dermatopathology, School of Medicine Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.

No abstract available

References

1. Esmaili N, Mortazavi H, Chams-Davatchi C, et al. Association between HLA-DQB1*03:01 and Bullous pemphigoid in Iranian patients. Iran J Immunol. 2013;10(1):1-9.
1. Zaraa I, Mahfoudh A, Sellami MK, et al. Lichen planus pemphigoides: four new cases and a review of the literature. Int J Dermatol. 2013;52(4):406-412. doi:10.1111/j.1365-4632.2012.05693.x
1. Cohen DM, Ben-Amitai D, Feinmesser M, Zvulunov A. Childhood lichen planus pemphigoides: a case report and review of the literature. Pediatr Dermatol. 2009;26:569-574.
1. Yoon KH, Kim SC, Kang DS, Lee IJ. Lichen planus pemphigoides with circulating autoantibodies against 200 and 180 kDa epidermal antigens. Eur J Dermatol. 2000;10:212-214.
1. Aryanian Z, Balighi K, Daneshpazhooh M, et al. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study. Int Immunopharmacol. 2021;96:107755. doi:10.1016/j.intimp.2021.107755